Free Trial
NYSE:ATNM

Actinium Pharmaceuticals 8/5/2024 Earnings Report

Actinium Pharmaceuticals logo
$1.38 -0.12 (-8.00%)
Closing price 05/6/2025 04:00 PM Eastern
Extended Trading
$1.39 +0.01 (+0.72%)
As of 05/6/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Actinium Pharmaceuticals EPS Results

Actual EPS
-$0.38
Consensus EPS
-$0.40
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Actinium Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Actinium Pharmaceuticals Announcement Details

Quarter
Time
TAS
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Actinium Pharmaceuticals Earnings Headlines

Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
See More Actinium Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Actinium Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Actinium Pharmaceuticals and other key companies, straight to your email.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals (NYSE:ATNM) develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

View Actinium Pharmaceuticals Profile

More Earnings Resources from MarketBeat